XML 93 R44.htm IDEA: XBRL DOCUMENT v3.3.1.900
Segment, Geographic and Other Revenue Information (Tables)
 12 Months Ended
Dec. 31, 2015
Segment Reporting [Abstract]  
Reconciliation of Revenue from Segments to Consolidated
The following table provides selected income statement information by reportable segment:
 
 
Revenues
 
Earnings(a)
 
Depreciation and Amortization(b)
 
 
Year Ended December 31,
 
Year Ended December 31,
 
Year Ended December 31,
(MILLIONS OF DOLLARS)
 
2015

 
2014

 
2013

 
2015

 
2014

 
2013

 
2015

 
2014

 
2013

Reportable Segments:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GIP
 
$
13,954

 
$
13,861

 
$
14,317

 
$
7,757

 
$
7,780

 
$
8,549

 
$
248

 
$
255

 
$
238

VOC
 
12,803

 
10,144

 
9,285

 
6,507

 
4,692

 
4,216

 
306

 
263

 
231

GEP(c)
 
21,587

 
25,149

 
27,619

 
12,885

 
16,199

 
17,552

 
422

 
475

 
478

Total reportable segments
 
48,345

 
49,154

 
51,221

 
27,149

 
28,671

 
30,318

 
976

 
993

 
947

Other business activities(d)
 
506

 
253

 
232

 
(2,950
)
 
(3,092
)
 
(2,828
)
 
98

 
91

 
105

Reconciling Items:
 
 

 
 

 
 
 
 

 
 

 
 
 
 
 
 
 
 
Corporate(e)
 
—

 
—

 
—

 
(5,430
)
 
(5,200
)
 
(5,689
)
 
354

 
384

 
432

Purchase accounting adjustments(e)
 
—

 
—

 
—

 
(3,953
)
 
(3,641
)
 
(4,344
)
 
3,573

 
3,782

 
4,487

Acquisition-related costs(e)
 
—

 
—

 
—

 
(894
)
 
(183
)
 
(376
)
 
75

 
53

 
124

Certain significant items(f)
 
—

 
198

 
132

 
(4,321
)
 
(3,749
)
 
(692
)
 
48

 
207

 
167

Other unallocated
 
—

 
—

 
—

 
(636
)
 
(567
)
 
(671
)
 
33

 
27

 
44

 
 
$
48,851

 
$
49,605

 
$
51,584

 
$
8,965

 
$
12,240

 
$
15,716

 
$
5,157

 
$
5,537

 
$
6,306

(a) 
Income from continuing operations before provision for taxes on income.
(b) 
Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.
(c) 
On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, and in accordance with our domestic and international reporting periods, our consolidated statement of income for the year ended December 31, 2015 reflects four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. See Note 2A for additional information.
(d) 
Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, which in 2015 includes the revenues and expenses related to our manufacturing and supply agreements with Zoetis. Other business activities also includes the costs managed by our WRD organization and our Pfizer Medical organization.
(e) 
For a description, see the “Other Costs and Business Activities” section above.
(f) 
Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
For Revenues in 2014 and 2013, certain significant items primarily represent revenues related to our manufacturing and supply agreements with Zoetis. For additional information, see Note 2D.
For Earnings in 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $584 million, (ii) foreign currency loss and inventory impairment related to Venezuela of $878 million, (iii) certain asset impairments of $787 million, (iv) a charge related to pension settlements of $491 million, (v) charges for business and legal entity alignment of $282 million, (vi) charges for certain legal matters of $968 million and (vii) other charges of $332 million. For additional information, see Note 3 and Note 4.
For Earnings in 2014, certain significant items includes: (i) charges for certain legal matters of $999 million, (ii) certain asset impairments of $440 million, (iii) a charge for an additional year of Branded Prescription Drug Fee of $215 million, (iv) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $598 million, (v) an upfront fee associated with collaborative arrangement with Merck KGaA of $1.2 billion, (vi) charges for business and legal entity alignment of $168 million and (vii) other charges of $165 million. For additional information, see Note 2C, Note 3 and Note 4.
For Earnings in 2013, certain significant items includes: (i) patent litigation settlement income of $1.3 billion, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.3 billion, (iii) net charges for certain legal matters of $21 million, (iv) certain asset impairments of $836 million, (v) the gain associated with the transfer of certain product rights to Hisun Pfizer of $459 million, (vi) costs associated with the separation of Zoetis of $18 million and (vii) other charges of $290 million. For additional information, see Note 2E, Note 3 and Note 4.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
The following table provides selected income statement information by reportable segment:
 
 
Revenues
 
Earnings(a)
 
Depreciation and Amortization(b)
 
 
Year Ended December 31,
 
Year Ended December 31,
 
Year Ended December 31,
(MILLIONS OF DOLLARS)
 
2015

 
2014

 
2013

 
2015

 
2014

 
2013

 
2015

 
2014

 
2013

Reportable Segments:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GIP
 
$
13,954

 
$
13,861

 
$
14,317

 
$
7,757

 
$
7,780

 
$
8,549

 
$
248

 
$
255

 
$
238

VOC
 
12,803

 
10,144

 
9,285

 
6,507

 
4,692

 
4,216

 
306

 
263

 
231

GEP(c)
 
21,587

 
25,149

 
27,619

 
12,885

 
16,199

 
17,552

 
422

 
475

 
478

Total reportable segments
 
48,345

 
49,154

 
51,221

 
27,149

 
28,671

 
30,318

 
976

 
993

 
947

Other business activities(d)
 
506

 
253

 
232

 
(2,950
)
 
(3,092
)
 
(2,828
)
 
98

 
91

 
105

Reconciling Items:
 
 

 
 

 
 
 
 

 
 

 
 
 
 
 
 
 
 
Corporate(e)
 
—

 
—

 
—

 
(5,430
)
 
(5,200
)
 
(5,689
)
 
354

 
384

 
432

Purchase accounting adjustments(e)
 
—

 
—

 
—

 
(3,953
)
 
(3,641
)
 
(4,344
)
 
3,573

 
3,782

 
4,487

Acquisition-related costs(e)
 
—

 
—

 
—

 
(894
)
 
(183
)
 
(376
)
 
75

 
53

 
124

Certain significant items(f)
 
—

 
198

 
132

 
(4,321
)
 
(3,749
)
 
(692
)
 
48

 
207

 
167

Other unallocated
 
—

 
—

 
—

 
(636
)
 
(567
)
 
(671
)
 
33

 
27

 
44

 
 
$
48,851

 
$
49,605

 
$
51,584

 
$
8,965

 
$
12,240

 
$
15,716

 
$
5,157

 
$
5,537

 
$
6,306

(a) 
Income from continuing operations before provision for taxes on income.
(b) 
Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.
(c) 
On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, and in accordance with our domestic and international reporting periods, our consolidated statement of income for the year ended December 31, 2015 reflects four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. See Note 2A for additional information.
(d) 
Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, which in 2015 includes the revenues and expenses related to our manufacturing and supply agreements with Zoetis. Other business activities also includes the costs managed by our WRD organization and our Pfizer Medical organization.
(e) 
For a description, see the “Other Costs and Business Activities” section above.
(f) 
Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
For Revenues in 2014 and 2013, certain significant items primarily represent revenues related to our manufacturing and supply agreements with Zoetis. For additional information, see Note 2D.
For Earnings in 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $584 million, (ii) foreign currency loss and inventory impairment related to Venezuela of $878 million, (iii) certain asset impairments of $787 million, (iv) a charge related to pension settlements of $491 million, (v) charges for business and legal entity alignment of $282 million, (vi) charges for certain legal matters of $968 million and (vii) other charges of $332 million. For additional information, see Note 3 and Note 4.
For Earnings in 2014, certain significant items includes: (i) charges for certain legal matters of $999 million, (ii) certain asset impairments of $440 million, (iii) a charge for an additional year of Branded Prescription Drug Fee of $215 million, (iv) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $598 million, (v) an upfront fee associated with collaborative arrangement with Merck KGaA of $1.2 billion, (vi) charges for business and legal entity alignment of $168 million and (vii) other charges of $165 million. For additional information, see Note 2C, Note 3 and Note 4.
For Earnings in 2013, certain significant items includes: (i) patent litigation settlement income of $1.3 billion, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.3 billion, (iii) net charges for certain legal matters of $21 million, (iv) certain asset impairments of $836 million, (v) the gain associated with the transfer of certain product rights to Hisun Pfizer of $459 million, (vi) costs associated with the separation of Zoetis of $18 million and (vii) other charges of $290 million. For additional information, see Note 2E, Note 3 and Note 4.
Reconciliation Of Depreciation And Amortization From Segments To Consolidated
The following table provides selected income statement information by reportable segment:
 
 
Revenues
 
Earnings(a)
 
Depreciation and Amortization(b)
 
 
Year Ended December 31,
 
Year Ended December 31,
 
Year Ended December 31,
(MILLIONS OF DOLLARS)
 
2015

 
2014

 
2013

 
2015

 
2014

 
2013

 
2015

 
2014

 
2013

Reportable Segments:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GIP
 
$
13,954

 
$
13,861

 
$
14,317

 
$
7,757

 
$
7,780

 
$
8,549

 
$
248

 
$
255

 
$
238

VOC
 
12,803

 
10,144

 
9,285

 
6,507

 
4,692

 
4,216

 
306

 
263

 
231

GEP(c)
 
21,587

 
25,149

 
27,619

 
12,885

 
16,199

 
17,552

 
422

 
475

 
478

Total reportable segments
 
48,345

 
49,154

 
51,221

 
27,149

 
28,671

 
30,318

 
976

 
993

 
947

Other business activities(d)
 
506

 
253

 
232

 
(2,950
)
 
(3,092
)
 
(2,828
)
 
98

 
91

 
105

Reconciling Items:
 
 

 
 

 
 
 
 

 
 

 
 
 
 
 
 
 
 
Corporate(e)
 
—

 
—

 
—

 
(5,430
)
 
(5,200
)
 
(5,689
)
 
354

 
384

 
432

Purchase accounting adjustments(e)
 
—

 
—

 
—

 
(3,953
)
 
(3,641
)
 
(4,344
)
 
3,573

 
3,782

 
4,487

Acquisition-related costs(e)
 
—

 
—

 
—

 
(894
)
 
(183
)
 
(376
)
 
75

 
53

 
124

Certain significant items(f)
 
—

 
198

 
132

 
(4,321
)
 
(3,749
)
 
(692
)
 
48

 
207

 
167

Other unallocated
 
—

 
—

 
—

 
(636
)
 
(567
)
 
(671
)
 
33

 
27

 
44

 
 
$
48,851

 
$
49,605

 
$
51,584

 
$
8,965

 
$
12,240

 
$
15,716

 
$
5,157

 
$
5,537

 
$
6,306

(a) 
Income from continuing operations before provision for taxes on income.
(b) 
Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.
(c) 
On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, and in accordance with our domestic and international reporting periods, our consolidated statement of income for the year ended December 31, 2015 reflects four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. See Note 2A for additional information.
(d) 
Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, which in 2015 includes the revenues and expenses related to our manufacturing and supply agreements with Zoetis. Other business activities also includes the costs managed by our WRD organization and our Pfizer Medical organization.
(e) 
For a description, see the “Other Costs and Business Activities” section above.
(f) 
Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
For Revenues in 2014 and 2013, certain significant items primarily represent revenues related to our manufacturing and supply agreements with Zoetis. For additional information, see Note 2D.
For Earnings in 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $584 million, (ii) foreign currency loss and inventory impairment related to Venezuela of $878 million, (iii) certain asset impairments of $787 million, (iv) a charge related to pension settlements of $491 million, (v) charges for business and legal entity alignment of $282 million, (vi) charges for certain legal matters of $968 million and (vii) other charges of $332 million. For additional information, see Note 3 and Note 4.
For Earnings in 2014, certain significant items includes: (i) charges for certain legal matters of $999 million, (ii) certain asset impairments of $440 million, (iii) a charge for an additional year of Branded Prescription Drug Fee of $215 million, (iv) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $598 million, (v) an upfront fee associated with collaborative arrangement with Merck KGaA of $1.2 billion, (vi) charges for business and legal entity alignment of $168 million and (vii) other charges of $165 million. For additional information, see Note 2C, Note 3 and Note 4.
For Earnings in 2013, certain significant items includes: (i) patent litigation settlement income of $1.3 billion, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.3 billion, (iii) net charges for certain legal matters of $21 million, (iv) certain asset impairments of $836 million, (v) the gain associated with the transfer of certain product rights to Hisun Pfizer of $459 million, (vi) costs associated with the separation of Zoetis of $18 million and (vii) other charges of $290 million. For additional information, see Note 2E, Note 3 and Note 4.
Revenue from External Customers by Geographic Areas
The following table provides revenues by geographic area:
 
 
Year Ended December 31,
(MILLIONS OF DOLLARS)
 
2015

 
2014

 
2013

United States(a)
 
$
21,704

 
$
19,073

 
$
20,274

Developed Europe(a), (b)
 
9,714

 
11,719

 
11,739

Developed Rest of World(a), (c)
 
6,298

 
7,314

 
8,346

Emerging Markets (a), (d)
 
11,136

 
11,499

 
11,225

Revenues
 
$
48,851

 
$
49,605

 
$
51,584


(a) 
On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, and in accordance with our domestic and international reporting periods, our consolidated statement of income for the year ended December 31, 2015 reflects four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. See Note 2A for additional information.
(b) 
Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries. Revenues denominated in euros were $7.4 billion in 2015, $9.0 billion in 2014 and $8.9 billion in 2013.
(c) 
Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea.
(d) 
Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey
Long-lived Assets by Geographic Areas
.
Long-lived assets by geographic region follow(a):
 
 
As of December 31,
(MILLIONS OF DOLLARS)
 
2015

 
2014

 
2013

Property, plant and equipment, net
 
 
 
 
 
 
United States
 
$
7,072

 
$
5,575

 
$
5,885

Developed Europe(b)
 
4,376

 
4,606

 
4,845

Developed Rest of World(c)
 
660

 
617

 
696

Emerging Markets(d)
 
1,658

 
963

 
971

Property, plant and equipment, net
 
$
13,766

 
$
11,762

 
$
12,397


(a) 
Reflects legacy Hospira amounts in 2015 commencing on the Hospira acquisition date, September 3, 2015.
(b) 
Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries.
(c) 
Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand, and South Korea.
(d) 
Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey
Schedule of Significant Product Revenues
The following table provides detailed revenue information:
 
 
Year Ended December 31,
(MILLIONS OF DOLLARS)
 
2015

 
2014

 
2013

INNOVATIVE PRODUCTS BUSINESS(a)
 
$
26,758

 
$
24,005

 
$
23,602

GIP(a)
 
$
13,954

 
$
13,861

 
$
14,317

Lyrica GIP(b)
 
3,655

 
3,350

 
2,965

Enbrel (Outside the U.S. and Canada)
 
3,333

 
3,850

 
3,774

Viagra GIP(c)
 
1,297

 
1,181

 
1,180

BeneFIX
 
752

 
856

 
832

Chantix/Champix
 
671

 
647

 
648

Genotropin
 
617

 
723

 
772

Refacto AF/Xyntha
 
533

 
631

 
602

Xeljanz
 
523

 
308

 
114

Toviaz
 
267

 
288

 
236

BMP2
 
232

 
228

 
209

Somavert
 
218

 
229

 
217

Rapamune
 
197

 
339

 
350

Alliance revenue GIP(d) (o)
 
1,254

 
762

 
1,878

All other GIP(e)
 
405

 
469

 
540

VOC(a)
 
$
12,803

 
$
10,144

 
$
9,285

Prevnar family(f)
 
6,245

 
4,464

 
3,974

Sutent
 
1,120

 
1,174

 
1,204

Ibrance
 
723

 
—

 
—

Xalkori
 
488

 
438

 
282

Inlyta
 
430

 
410

 
319

FSME-IMMUN/TicoVac
 
104

 
—

 
—

All other V/O(e)
 
298

 
211

 
164

Consumer Healthcare
 
3,395

 
3,446

 
3,342

ESTABLISHED PRODUCTS BUSINESS(g)
 
$
21,587

 
$
25,149

 
$
27,619

Legacy Established Products(h)
 
$
11,745

 
$
13,016

 
$
14,089

Lipitor
 
1,860

 
2,061

 
2,315

Premarin family
 
1,018

 
1,076

 
1,092

Norvasc
 
991

 
1,112

 
1,229

Xalatan/Xalacom
 
399

 
495

 
589

Zoloft
 
374

 
423

 
469

Relpax
 
352

 
382

 
359

EpiPen
 
339

 
294

 
273

Effexor
 
288

 
344

 
440

Zithromax/Zmax
 
275

 
311

 
387

Xanax/Xanax XR
 
224

 
253

 
276

Cardura
 
210

 
263

 
296

Neurontin
 
196

 
210

 
216

Diflucan
 
181

 
208

 
238

Tikosyn
 
179

 
141

 
119

Depo-Provera
 
170

 
201

 
191

Unasyn
 
118

 
96

 
84

All other Legacy Established Products(e), (o)
 
4,571

 
5,145

 
5,516

Peri-LOE Products(i)
 
$
5,326

 
$
8,855

 
$
10,151

Lyrica GEP(b)
 
1,183

 
1,818

 
1,629

Zyvox
 
883

 
1,352

 
1,353

Celebrex
 
830

 
2,699

 
2,918

Pristiq
 
715

 
737

 
698

Vfend
 
682

 
756

 
775

Viagra GEP(c)
 
411

 
504

 
701

Revatio
 
260

 
276

 
307

All other Peri-LOE Products(e)
 
362

 
714

 
1,770

Sterile Injectable Pharmaceuticals(j)
 
$
3,944

 
$
3,277

 
$
3,378

Medrol
 
402

 
381

 
398

Sulperazon
 
339

 
354

 
309

Fragmin
 
335

 
364

 
359

Tygacil
 
304

 
323

 
358

All other Sterile Injectable Pharmaceuticals(e)
 
2,563

 
1,855

 
1,954

Infusion Systems(k)
 
$
403

 
$
—

 
$
—

Biosimilars(l)
 
$
63

 
$
—

 
$
—

Other Established Products(m)
 
$
106

 
$
—

 
$
—

OTHER(n)
 
$
506

 
$
451

 
$
364

Revenues
 
$
48,851

 
$
49,605

 
$
51,584

Total Lyrica(b)
 
$
4,839

 
$
5,168

 
$
4,595

Total Viagra(c)
 
$
1,708

 
$
1,685

 
$
1,881

Total Alliance revenues(o)
 
$
1,312

 
$
957

 
$
2,628

(a) 
The Innovative Products business is composed of two operating segments: GIP and VOC.
(b) 
Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica-GEP. All other Lyrica revenues are included in Lyrica-GIP. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica-GIP and Lyrica-GEP.
(c) 
Viagra revenues from the U.S. and Canada are included in Viagra-GIP. All other Viagra revenues are included in Viagra-GEP. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra-GIP and Viagra-GEP.
(d) 
Includes Eliquis, Rebif and Enbrel (in the U.S. and Canada through October 31, 2013).
(e) 
All other GIP and All other V/O are a subset of GIP and VOC, respectively. All other Legacy Established Products, All other Peri-LOE Products and All other Sterile Injectable Pharmaceuticals are subsets of Established Products.
(f) 
In 2015, all revenues were composed of Prevnar 13/Prevenar 13. In 2014 and 2013, revenues were composed of the Prevnar family of products, which included Prevnar 13/Prevenar 13 and, to a much lesser extent, Prevenar (7-valent).
(g) 
The Established Products business consists of GEP, which includes all legacy Hospira commercial operations. Commencing from the acquisition date, September 3, 2015, and in accordance with our domestic and international reporting periods, our consolidated statement of income, primarily GEP’s operating results, for the year ended December 31, 2015 reflects four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations.
(h) 
Legacy Established Products include products that lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products).
(i) 
Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products primarily include Celebrex, Zyvox and Revatio in most developed markets, Lyrica in the EU, Pristiq in the U.S. and Inspra in the EU.
(j) 
Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products).
(k) 
Infusion Systems include Medication Management Systems products composed of infusion pumps and related software and services, as well as I.V. Infusion Products, including large volume I.V. solutions and their associated administration sets.
(l) 
Biosimilars include Inflectra (biosimilar infliximab), Nivestim (biosimilar filgrastim) and Retacrit (biosimilar epoetin zeta) in certain international markets.
(m) 
Includes legacy Hospira’s One-to-One contract manufacturing and bulk pharmaceutical chemical sales organizations.
(n) 
Other includes revenues from Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales organization, and revenues related to our manufacturing and supply agreements with Zoetis.
(o) 
Total Alliance revenues represent the aggregate of worldwide revenues from Alliance revenues GIP and Alliance revenues GEP, which is included in All other Legacy Established Products.